Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol. 2018

Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
University of Modena and Reggio Emilia, Cardiology Unit, Pulmonary Hypertension Program, Policlinico di Modena Hospital, Italy. Electronic address: rosario.rossi@unimore.it.

Exogenous intravenous (IV) adenosine and epoprostenol are effective vasodilator agents, causing a substantial reduction in pulmonary vascular resistance in patients affected by idiopathic pulmonary arteriolar hypertension (PAH). Their action, in patients with PAH associated with other pathological conditions, is not well defined. In the present paper the authors retrospectively analyzed the acute hemodynamic effects of intravenous adenosine and epoprostenol in 30 consecutive patients (mean age: 58 ± 15 years; 21 females, and 9 males) affected by PAH associated with other pathological conditions, as determined by changes from baseline in systemic and pulmonary hemodynamic parameters. Acute IV administration of adenosine decreased pulmonary vascular resistance index (PVRI) by 3 Wood U/m2 (- 20%) compared to baseline (p = 0.02). We noted a slight, not significant, decrease in mean pulmonary artery pressure (mPAP) of 4 mmHg. Cardiac index (CI) increased by 0.5 L/min/m2 (15% increase respect to baseline; p = 0.03). The heart rate and mean systemic blood pressure (BP) did not change significantly. Acute IV administration of epoprostenol decreased PVRI by 6 mmHg (- 40%) respect to baseline (p < 0.0001). CI increased by 1.4 L/min/m2 (p < 0.0001); while mPAP decreased by 5 mmHg (nearly 10%) (p = 0.04). This decrease of mPAP was accompanied by a mean BP decrease of 11 mmHg compared to baseline (p = 0.003). Our results indicates that, in patients with PAH associated with other pathological conditions, adenosine is predominantly a positive inotropic agent; and epoprostenol a potent vasodilator of both pulmonary and systemic vessels, and a strong positive inotropic agent.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan

Related Publications

Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
January 2005, Congestive heart failure (Greenwich, Conn.),
Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
January 2013, Pulmonary circulation,
Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
October 2009, The Journal of rheumatology,
Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
April 2019, American journal of cardiovascular drugs : drugs, devices, and other interventions,
Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
January 2007, Journal of cardiovascular pharmacology,
Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
October 2000, Chest,
Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
April 2022, Pulmonary circulation,
Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
July 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
March 2007, The American journal of cardiology,
Rosario Rossi, and Francesca Coppi, and Fabio Sgura, and Daniel Monopoli, and Giuseppe Boriani
January 2005, Indian heart journal,
Copied contents to your clipboard!